hat
Spronck EA, et al. Amelyore Aktivite Faktè IX apre Administrasyon AAV5-R338L Faktè IX "Padova" kont AAV5 WT Faktè Imèn IX nan NHP yo. Mol Ther Methods Klin Dev. 2019; 15: 221-231.
eng
Spronck EA, et al. Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs. Mol Ther Methods Clin Dev. 2019;15:221-231.